Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.

Magnani E, Farnetti E, Nicoli D, Casali B, Savoldi L, Focaccetti C, Boni C, Albini A, Banzi M.

Intern Emerg Med. 2013 Aug;8(5):417-23. doi: 10.1007/s11739-013-0936-8.

PMID:
23585145
2.

Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.

Bank PC, Guchelaar HJ, Swen JJ.

Intern Emerg Med. 2014 Jun;9(4):481-2. doi: 10.1007/s11739-013-1027-6. No abstract available.

PMID:
24310106
3.

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.

Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C.

Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56. doi: 10.1007/s00280-010-1282-4.

PMID:
20204365
5.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Hungarian.

8.

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

Hooiveld EA, van Kuilenburg AB, Haanen JB, Westermann AM.

Ned Tijdschr Geneeskd. 2004 Mar 27;148(13):626-8. Dutch.

PMID:
15083629
10.

A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.

Blasco H, Boisdron-Celle M, Bougnoux P, Calais G, Tournamille JF, Ciccolini J, Autret-Leca E, Le Guellec C.

Br J Clin Pharmacol. 2008 Jun;65(6):966-70. doi: 10.1111/j.1365-2125.2008.03106.x. No abstract available.

11.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2013 Dec;94(6):640-5. doi: 10.1038/clpt.2013.172.

12.

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

van Kuilenburg AB.

Eur J Cancer. 2004 May;40(7):939-50. Review.

PMID:
15093568
13.

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG.

Clin Pharmacokinet. 2012 Mar 1;51(3):163-74. doi: 10.2165/11595880-000000000-00000.

PMID:
22339448
14.

High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.

Gross E, Seck K, Neubauer S, Mayr J, Hellebrand H, Ratanaphan A, Lutz V, Stockinger H, Kiechle M.

Int J Oncol. 2003 Feb;22(2):325-32.

PMID:
12527930
15.

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A.

Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209.

16.

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH.

Clin Cancer Res. 2001 May;7(5):1149-53.

17.

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.

Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH.

Pharmacogenetics. 2002 Oct;12(7):555-8.

PMID:
12360106
18.

[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].

Coursier S, Martelet S, Guillermet A, Emptoz J, Villier C, Bontemps H.

Gastroenterol Clin Biol. 2010 Mar;34(3):218-23. doi: 10.1016/j.gcb.2009.08.014. French.

19.

Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.

van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH.

Clin Cancer Res. 2000 Dec;6(12):4705-12.

20.

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].

Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH.

Ned Tijdschr Geneeskd. 2012;156(48):A4934. Dutch.

PMID:
23191966
Items per page

Supplemental Content

Support Center